Objective. We aimed to validate the Oudega diagnostic decision rule-which was developed and validated among younger aged primary care patients-to rule-out deep vein thrombosis (DVT) in frail older outpatients. Methods. In older patients (>60 years, either community dwelling or residing in nursing homes) with clinically suspected DVT, physicians recorded the score on the Oudega rule and d-dimer test. DVT was confirmed with a composite reference standard including ultrasonography examination and 3-month follow-up. The proportion of patients with a very low probability of DVT according to the Oudega rule (efficiency), and the proportion of patients with symptomatic venous thromboembolism during 3 months follow-up within this 'very low risk' group (failure rate) was calculated. Results. DVT occurred in 164 (47%) of the 348 study participants (mean age 81 years, 85% residing in nursing homes). The probability of DVT was very low in 69 patients (Oudega score ≤3 points plus a normal d-dimer test; efficiency 20%) of whom four had non-fatal DVT (failure rate 5.8%; 2.3-14%). With a simple revised version of the Oudega rule for older suspected patients, 43 patients had a low risk of DVT (12% of the total population) of whom only one had DVT (failure rate 2.3%; 0.4-12%). Conclusions. In older suspected patients, application of the original Oudega rule to exclude DVT resulted in a higher failure rate as compared to previous studies. A revised and simplified Oudega strategy specifically developed for elderly suspected patients resulted in a lower failure rate though at the expense of a lower efficiency.
Introduction
Leg complaints occur relatively frequent in older patients (1) . Deep vein thrombosis (DVT), which predominantly occurs at an advanced age, is one of the more serious conditions in the differential diagnosis: missing DVT poses patients at risk of possibly fatal pulmonary embolism (2) . Yet-given the often non-specific complaints in these patients-many older patients are suspected of DVT, whereas it can be confirmed in only one in five of those suspected cases (3) (4) (5) . Referring all patients for reference testing (venous imaging) can be burdensome for frail older patients as they are vulnerable for distress and complications resulting from the journey to a hospital and the undergoing of diagnostic tests (6, 7) . Hence, the difficulty in the diagnostic workup of DVT in such patients is to adequately and timely distinguish those in whom referral and treatment can be safely withheld from those who really need to be referred to hospital care facilities for confirmation of the diagnosis and subsequent anticoagulant treatment.
To help the physician identifying those patients with a high probability of DVT from those with a very low risk of DVT (and thus do not need referral), clinical decision rules-based on a weighed combination of signs and symptoms including d-dimer testing-have been developed. The Wells' rule is probably the most widely known clinical decision rule for this purpose, and it is extensively validated in hospital and emergency care settings (8, 9) . As this rule appeared to be unsafe in a study in primary care patients suspected of having DVT, the Oudega rule has subsequently been proposed to exclude DVT in primary care patients (10, 11) . In a management study on this Oudega diagnostic decision rule (performed in primary care; n = 1028), we found that physicians could refrain from referral to hospital care in almost half of all suspected patients (49%), yielding a commonly accepted proportion of 1.4% of missed DVT cases in this low-risk group (95% confidence interval: 0.6-2.9%) (12) . The benefits of such a strategy might particularly apply for frail older patients, provided that it can also safely rule-out DVT in this specific domain. However, diagnostic decision strategies tend to perform worse when applied outside the setting as where they are derived from and validated in (13, 14) . Moreover, the d-dimer concentration increases with age and its specificity for venous thromboembolism (VTE) consequently decreases in elderly patients (15, 16) . This leads to more false positive d-dimer test results in the older patients (5) . Strikingly though, the accuracy of diagnostic decision strategies in suspected DVT (i.e. the strategy's ability to discriminate patients without DVT from those with DVT) has never been formally investigated in frail older patients. We therefore conducted this prospective external validation study to evaluate the accuracy of the Oudega diagnostic decision rule combined with d-dimer testing to safely exclude DVT in older out-of-hospital patients (10, 12, 13) . In addition, a post-hoc analysis evaluated the Wells rule for this purpose in these patients and tested whether the Oudega rule required updating in order to safely rule-out DVT in this specific care setting.
Methods

Setting and participants
The Venous Thromboembolism in the Elderly (VT-elderly) study was a prospective observational study with 3 months follow-up. Older patients residing in nursing homes or community-dwelling patients (≥60 years) with clinically suspected DVT (based on pain, swelling or redness of the lower extremity) were included by elderly care physicians and GPs across the Netherlands between October 2008 and April 2013. Patients were excluded if they denied providing informed consent or if they received treatment with anticoagulants at presentation (coumarins or oral direct thrombin or factor Xa inhibitors). The local ethics review board of the University Medical Center Utrecht, the Netherlands, judged the study as exempt from review according to the national law (08-124/E).
Diagnostic strategy under study
Physicians systematically recorded medical history, signs, symptoms and the result on the Oudega rule for each patient (please see online supplementary material 1) (10, 12) . The diagnostic variables in the Oudega rule are; male gender, oestrogen use (or hormonal replacement therapy), presence of malignancy, recent surgery, absence of trauma, collateral vein distension (all contributing for 1 point), calf circumference difference ≥3 cm (contributing for 2 points) and d-dimer testing contributing for 6 points if abnormal. Physicians were provided with qualitative point-of-care d-dimer tests (Clearview Simplify D-dimer assay®) and with written instructions on how to perform and interpret this test. They either applied this point-of-care test (for 70% of the study participants) or used the results of quantitative d-dimer assays in local laboratories for which values of 500 μg/l and higher were considered abnormal. Though in this validation study referral for compression ultrasonography examination of the lower extremity was recommended for all patients who had a total score >3 on the Oudega rule, it was left to the physicians' discretion whether patients were indeed referred. If the patient was considered to have a very low probability of DVT (based on a total score on the Oudega rule ≤3 points), imaging and anticoagulant treatment were not recommended.
Outcome assessment
The primary endpoint of this study was the presence of VTE during 3-month follow-up. At 3 months, follow-up was performed for all patients to assess the occurrence of any VTE event and-if applicable-cause of death. All patients who were not referred to a hospital for objective testing despite a score >3 on the Oudega rule were evaluated by an adjudication committee of three experts (two GPs who specialized in thrombotic disorders and one geriatrician specialized in cardiovascular diseases in older patients). Ifbased on signs, symptoms, d-dimer testing and all other available clinical information-VTE was deemed present by the committee, patients were classified accordingly. Similarly, this committee also adjudicated-if applicable-the cause of death ('likely' or 'unlikely' related to VTE).
Hence, in this study, VTE was considered present if (i) there was a finding of DVT on lower limb ultrasonography; or (ii) confirmed pulmonary embolism on computed tomography pulmonary angiography of the chest; or (iii) death within 3 months probably related to VTE as assessed by an adjudication committee or (iv) if patients were adjudicated as VTE present.
Statistical analyses
Some participants had missing values for clinical items of the Oudega rule, the d-dimer test, or in follow-up data (4.6%; 6.1% and 0.9%, respectively). To minimize bias associated with selectively ignoring these patients. We used multiple imputation with the chained equations (MICE) and created 10 imputed datasets (given the 'at random' pattern of missingness) (17, 18) . The primary analysis included the proportion of patients with symptomatic VTE during 3 months follow-up within those with a very low risk on the Oudega decision rule (total ≤3 points; this is the failure rate), as well as the proportion of very low-risk patients among the total suspected population (efficiency). For calculation of 95% confidence intervals, the exact binomial Wilson Score method was used (19) .
In addition, we performed post-hoc analyses. First, we calculated the proportion of patients with symptomatic VTE during 3 months follow-up within those with a high risk on the Oudega decision rule (total >10 points; the positive predictive value). Second, we refitted the eight variables originally included on the Oudega decision rule within our population. We thereby re-estimated all coefficients and the intercept and subsequently performed backward elimination, retaining those predictors, that were statistically significantly associated with VTE in the multivariable model, based on the log likelihood ratio test at P value <0.10. This model was adjusted for overfitting using bootstrapping techniques (20) .
Third, we estimated the efficiency and failure rate for patients with an 'unlikely' (≤1) probability for DVT according to the Wells rule, combined with a normal d-dimer test, as well as its positive predictive value (21) . All analyses were performed using R-2.15.3 (packages RMS and MICE).
Results
Participants
Data were prospectively collected of 394 patients suspected of having DVT by their physician (291 physicians in total employed in 109 practices, notably nursing homes) of whom 46 patients were excluded based on predefined exclusion criteria (see the flowchart; Fig. 1 ). A total of 348 participants (26% males, mean age 81 years) were included in the study, the majority of them (n = 294, 85%) residing in nursing homes. Almost half of the participants (49%) were bedridden or chairbound and 42 participants (12%) had an active malignancy (Table 1) .
VTE was deemed present in 164 patients (47%). A total of 45 study participants died during the 3-month follow-up (3-month mortality rate 13%) and in four of these patients (8.9%) VTE was presumed as probable cause of death. Major bleeding or a clinically relevant non-major bleeding occurred in 14 patients during the 3 months follow-up (4.0%).
Accuracy of the original Oudega rule
Among the 348 study participants, 69 had a score of 3 or lower on the Oudega rule (20% of the total population; 95% confidence interval: 16-24%; Table 2 ). In the 3 months follow-up, VTE was confirmed in four of these patients (failure rate 5.8%; 2.3-14%). For details of these patients, please see online supplementary material 2. Lowering the threshold on the Oudega rule did not significantly reduce the failure rate [which was 6.3% (2.1-17%) and 3.2% (0.6-16.8%) for a score ≤2 and ≤1 respectively; see online supplementary material 3].
VTE was diagnosed in 55 of the 80 patients with a high risk (score >10) according to the Oudega rule (23% of the total population, positive predictive value of 69%; 58-78%).
Accuracy of the Wells rule
If physicians would have used the Wells score for DVT, a total of 61 study participants would have a combination of the Wells rule indicating an unlikely (≤1) probability of DVT and a normal d-dimer test (efficiency 18%; 14-22%; Table 3 ). Three of these patients were diagnosed with VTE (failure rate 4.9%; 1.7-14%).
A total of 175 patients (50% of the total population) had a combination of an abnormal d-dimer test and a 'likely' (≥2) probability according to the Wells rule of whom 123 were diagnosed with VTE (positive predictive value of 70%; 63-77%).
Refitting
When refitting the Oudega model in our population of older patients (See online supplementary material 4), only three variables (calf Figure 1 . Flow of participants through the study, using the Oudega strategy (10). 
Validation of the Oudega diagnostic decision rule
Discussion
We performed a validation study on a diagnostic decision rule (i.e. the Oudega rule) to rule-out DVT in frail older outpatients (10, 12, 22) . The proportion of patients in whom VTE could be ruledout was lower than expected, as based on previous validation studies in younger patients. These previous studies demonstrated that imaging examinations (and thus treatment) could be safely withheld in up to 50% of patients, whereas in our study this exclusion proportion was only 20% (12) . In addition, the overall prevalence of VTE was more than twice as high in our elderly study population: 47% as compared to a prevalence between 7% and 20% in previous studies. As a result, patients had a much higher prior-probability for VTE which expectedly also led to a more than 2-fold higher proportion of 'missed' DVT cases in those patients classified as 'very low-risk' (failure rate of 5.8%, as compared to 1-2% in previous studies) (9, 10, 12, 23) . However, the strategy did make a substantial reduction from the 47% pre-test probability to the 5.8% post-test probability in the patients in the very low-risk category.
Strengths and limitations of the study
To our best knowledge, this study is the first to evaluate the use of a diagnostic decision rule in suspected DVT in this vulnerable elderly population. Notably frail older patients might benefit from such a strategy provided that it can safely rule-out VTE in a substantial proportion of them without needing to be referred for imaging examination. Yet, for full appreciation of our results, some aspects warrant comment. First, we found a high prevalence of VTE in our study, which might reflect selective inclusion of only high-risk patients. However, as said, our study population represents a very old (mean age above 80 years) and frail nursing home population with a short life expectancy (3 months all-cause mortality rate 13%) and many co-morbidities (Table 1) . Age, nursing home confinement, immobility and co-morbidity are all strong risk factors for VTE and thus most likely have contributed to the high prevalence of VTE in our study population (2, 3, 24) . Second, the presence or absence of VTE was defined with combined reference tests; ultrasound and 3 months follow-up, including adjudication (25) . For instance, in patients with a low score on the Oudega rule, we had to rely on clinical follow-up only to detect any missed thromboembolic disease. Thus, the false negative cases were patients with a score of 3 or lower with severe symptoms or worsening or recurrence of their symptoms within 3 months, leading to further examinations and the detection of VTE. Although this is common in VTE research, small (clinically less relevant) thrombi may have been missed in these patients, and thus the false negative rate might be somewhat underestimated.
Third, we recommended referring patients with a score >3 points on the Oudega rule for a leg ultrasound, though our protocol allowed this decision to be made at the physicians' discretion. Nevertheless 75 of those patients (22% of all included patients) did not undergo this reference test. As it is likely that imaging examinations were notably withheld in the frailest patients, we chose to avoid selectively ignoring of these patients as doing so would have resulted in biased estimates (i.e. selection bias) (25) . Instead, the presence or absence of VTE in these patients was defined by an adjudication committee who decided on each of these 75 patients whether it was likely or unlikely that VTE was present, on the basis of all clinical characteristics, physicians' treatment decisions and the clinical course. This differential verification might have introduced some misclassification of the outcome, though we believe it does reflect daily clinical practice. For this reason we focused-according to methodological standards-on predictive values (i.e. failure rate) rather than on estimates of the sensitivity as the former are not affected by differential verification (25) . Predictive values (such as the failure rate and efficiency) depend on disease prevalence and therefore vary across (clinically relevant) subgroups. However, the same problem holds for sensitivity and specificity (26) .
Fourth, during the study it became evident that d-dimer testing in very old patients yields a very low proportion of negative results. Even in absence of VTE, d-dimer tests are often abnormal in older patients (5) . As a result, the number of patients in the 'very low risk' category was lower than we had expected, which led to wide confidence intervals among the calculated VTE prevalence in the patients in the low-risk categories.
Finally, we used a qualitative point-of-care assay, which has a somewhat lower sensitivity than the high-sensitive enzyme-linked immunosorbent assays commonly used nowadays. This might have increased the failure rate in our study (27) .
Clinical implications
Based on consensus among experts in the field of VTE, current guidelines state that a diagnostic strategy for DVT is considered as safe if its failure rate would be at or below 2% (28) . When adhering to this safety standard, one has to consider the original Oudega rule as unsafe strategy for frail elderly out-of-hospital patients suspected of having DVT. Accordingly, this would actually imply that all frail older patients with any clinical suspicion of DVT should then be referred for imaging examinations of the leg. As this seems unappealing and unrealistic for this frail population, we like to place these findings in perspective. In the current study we found that physicians withheld referral for additional diagnostic workup anyhow in 27% of patients despite a score >3 on the Oudega rule. Clearly, the potential risks and burden of hospital transfers for frail older patients (e.g. functional decline, risk of falling) implicitly played a role already in this decision making (6, 7) . Nevertheless, the medical profession may consider the failure rate of 5.8% or the referral rate of 80% of the diagnostic strategy as found in our study still as unacceptably high. This prompted us to perform post-hoc investigations on the performance of other strategies in a frail older population suspected of DVT. These analyses-including the use of a lower threshold on the Wells rule and even the fitting of a new model (See online supplementary material 5)-demonstrated that a lower failure rate of 2.1% could indeed be achieved, yet at the expense of a much lower efficiency of 12% or 14% (See online supplementary materials 4 and 5).
We also found that, in this distinct patient population, irrespectively of the applied strategy, a subgroup of patients with a post-test probability of 68-75% could be identified (see Tables 2 and 3 and see online supplementary material 5). Possibly in patients with such a 'very high risk' of VTE, anticoagulant treatment may indeed be directly initiated, if referral of the patient is deemed undesirable. The drawback of such a 'rule-in strategy' is that one in three of these frail patients would be exposed to the risks and burden of anticoagulant therapy while no VTE is present. This 'rule-in' approach needs to be validated in other samples of frail older suspected patients and its acceptability should be discussed among health care professionals before we can recommend its use in practice (14) .
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